Georgia’s HIV infection rate dropped by a 6 percent annual rate from 2008 to 2014, the Centers for Disease Control and Prevention has reported. The state Department of Health said Monday that the decline “is very encouraging news for Georgia as we work to eliminate HIV/AIDS in the state.” Dr. Patrick O’Neal, director of health […]
Georgia sees significant drop in HIV infection rate Read More »
Latest stats offer ‘encouraging news’ in fight against HIV/AIDS ATLANTA – Georgia’s HIV infection rate dropped by a 6 percent annual rate from 2008 to 2014, the CDC has reported. The state Department of Health said Monday that the decline “is very encouraging news for Georgia as we work to eliminate HIV/AIDS in the state.”
Georgia, national HIV infection rates drop Read More »
AIDS Healthcare Foundation (AHF) welcomed the news last week of an 18% decline in HIV infections in the United States between 2008 and 2014, but is questioning some of the conclusions drawn by Centers for Disease Control and Prevention (CDC) officials regarding the role of pre-exposure prophylaxis (PrEP), in particular, in the decline. In addition,
Bob Leahy and the myth that because PrEP very occasionally has failed, the reliability of a sustained undetectable viral load as an effective prevention strategy for people living with HIV needs questioning The HIV world was jumping, if not jittery, last week, with a third case of HIV pre-exposure prophylaxis (PrEP) failure reported, this time,
Don’t be fooled: PrEP failures imply nothing about U = U Read More »
An outreach nurse with the Interior Health Authority shares her story.
Filling Gaps to Provide HIV Care in Rural Regions Read More »
SEATTLE — Unrestricted use of new direct-acting agents against hepatitis C (HCV) can markedly reduce the rate of new infections, a researcher said here. That’s based on analysis of what happened in the Netherlands among gay men with both HIV and HCV when unlimited access to the new, highly effective agents was rolled out in
Wide Use of New HCV Drugs Prevents New Cases Read More »
In this issue, HCV Next asks five questions of Anita Howe, PhD, scientific leader for hepatitis C at the British Columbia Center for Excellence for HIV/AIDS. Howe completed her PhD in Medical Microbiology and Immunology at the University of Alberta, Canada. Her main area of focus was nucleoside inhibitors against hepatitis B virus. A fellowship
A Conversation With Anita Howe, PhD Read More »
An image of the moment I was diagnosed HIV positive remains vivid in my mind. The feelings and emotions that ran through my body like a lightening bolt that day are not easily forgotten. They will be with me forever, as will my feeling of infectiousness upon hearing the words that have played in my
While their guidelines are effective, they sometimes don’t feel realistic for queer people According to the Centres for Disease Control (CDC), the only way to reduce the risk of contracting sexually transmitted infections (STIs) including gonorrhea is to avoid vaginal, anal or oral sex altogether. That’s not an option for most of us, particularly those
Are public health recommendations sex-negative? Read More »
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
